Vaporox develops a medical device that utilizes advanced negative pressure wound therapy to promote healing in diabetic foot ulcers and skin wounds. This technology enhances blood flow and accelerates tissue regeneration, addressing the significant challenge of slow-healing wounds in diabetic patients.
Funding
$12.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diabetic foot ulcers and other chronic skin wounds present a significant challenge due to impaired blood flow and reduced tissue regeneration. Traditional wound care methods often prove inadequate, leading to prolonged healing times, increased risk of infection, and potential amputation.
Solution
Vaporox has developed a medical device employing advanced negative pressure wound therapy (NPWT) to accelerate the healing of diabetic foot ulcers and various skin wounds. The device applies controlled negative pressure to the wound site, enhancing microcirculation and promoting the formation of granulation tissue. This enhanced blood flow delivers essential nutrients and oxygen to the wound bed, stimulating cellular activity and accelerating tissue regeneration. By optimizing the wound environment, Vaporox's NPWT system aims to reduce healing times, minimize complications, and improve patient outcomes.
Target Audience
The primary target audience includes podiatrists, wound care specialists, hospitals, and clinics treating patients with diabetic foot ulcers, pressure ulcers, surgical wounds, and other chronic skin wounds.
Features
- Controlled negative pressure application to optimize wound healing
- Enhanced microcirculation and tissue regeneration through NPWT
- Portable and user-friendly design for convenient application
- Real-time monitoring of pressure levels and wound status
- Customizable treatment parameters to suit individual patient needs